Skip to main content
S&P 5007,818.93+0.58%DOW51,521.28+0.49%NASDAQ27,599.79+0.45%BTC$85,618.00-0.20%ETH$2,695.89-0.68%GOLD$4,191.90+0.84%OIL$89.82+0.44%
Smart Investors Daily
SID Premium
Karyopharm Therapeutics Inc. logo

NASDAQ · KPTI

Karyopharm Therapeutics Inc.

Healthcare · Biotechnology

$0.67

Down-$0.02 (-3.07%)

Updated Oct 6, 2026, 8:41 PM

SID Score

2.8/10

Composite research score

Smart Money

—

Institutional and insider signal

Market cap
59.5M
P/E ratio
-0.48
Dividend yield
0.00%
52-week range
$0.63 – $10.86
Volume
1.98M
Avg. volume
181.65K

Price performance · KPTI

KPTI price history

1M range · 20 trading sessions · Daily adjusted prices

Prices through Oct 5, 2026

KPTI closed at $0.67 after 20 trading sessions, down 61.02% for the selected period.

Last close
$0.67
Period change
-61.02%
Period low
$0.67
Period high
$1.88
Daily close
View OHLC price history
KPTI OHLC price history, latest 40 sessions
DateOpenHighLowCloseVolume
Oct 5, 2026$0.8022$0.8023$0.6259$0.67051.98M
Oct 2, 2026$0.857$0.8938$0.7471$0.80222.34M
Oct 1, 2026$1.19$1.20$0.8477$0.86682.66M
Sep 30, 2026$1.26$1.27$1.18$1.221.75M
Sep 29, 2026$1.62$1.625$1.20$1.2051.87M
Sep 28, 2026$1.59$1.66$1.54$1.62331.07K
Sep 25, 2026$1.73$1.77$1.565$1.621.47M
Sep 24, 2026$1.73$1.77$1.71$1.73677.36K
Sep 23, 2026$1.81$1.84$1.66$1.75957.51K
Sep 22, 2026$1.87$1.92$1.78$1.82986.9K
Sep 21, 2026$1.85$1.93$1.78$1.861.62M
Sep 18, 2026$1.77$1.885$1.6701$1.881.9M
Sep 17, 2026$1.7465$1.85$1.655$1.791.09M
Sep 16, 2026$1.54$1.72$1.54$1.701.35M
Sep 15, 2026$1.59$1.70$1.525$1.541.33M
Sep 14, 2026$1.55$1.62$1.55$1.60991.81K
Sep 11, 2026$1.50$1.61$1.24$1.616.74M
Sep 10, 2026$1.68$1.68$1.595$1.62800.95K
Sep 9, 2026$1.72$1.75$1.65$1.69772.57K
Sep 8, 2026$1.77$1.79$1.70$1.721.01M

Latest KPTI news

The latest Smart Investors Daily articles mentioning KPTI.

Stock researchCompany · Overview

KPTI research

Overview

Company profile and research snapshot.

Company profile

Karyopharm Therapeutics Inc is a commercial-stage pharmaceutical company pioneering novel cancer therapies and dedicated to the discovery, development, and commercialization of drugs directed against nuclear export for the treatment of cancer and other diseases. XPOVIO (selinexor), is approved in the U.S. in multiple hematologic malignancy indications, including in combination with Velcade (bortezomib) and dexamethasone for the treatment of adult patients with multiple myeloma after at least one prior therapy, in combination with dexamethasone for the treatment of adult patients with heavily pretreated multiple myeloma and as a monotherapy for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma. The company derives its revenue from United States.

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
—
Average target
$15.25
Implied upside
—
Analysts
—
KPTI recent ratings
DateFirmRatingTarget
Jul 31, 2026Piper SandlerOverweight—
Jul 31, 2026HC Wainwright & Co.Neutral—
May 6, 2026HC Wainwright & Co.Buy—
Apr 27, 2026Piper SandlerOverweight—
Mar 30, 2026Piper SandlerOverweight—
Open full forecast

News briefing

No generated briefing is available yet.

Yahoo · Oct 1, 2026

Karyopharm Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced that the Company granted 333 restricted stock units (RSUs) to one newly-hired employee. This RSU award was granted as of September 30, 2026 (the "Grant Date") pursuant to the Company's 2022 Inducement Stock Incentive Plan, as amended, as an inducement material to the new employee entering into employment with Karyopharm in accordance with Nasdaq Listing Rule 5

Benzinga · Sep 11, 2026

12 Health Care Stocks Moving In Friday's Pre-Market Session

Gainers Tenon Medical (NASDAQ:TNON) shares moved upwards by 49.2% to $7.91 during Friday's pre-market session. The company's market cap stands at $3.5 million. Biodexa Pharmaceuticals (NASDAQ:BDRX) stock rose

AI research layers

Interpretive context generated from the platform’s current data sources.

No results

AI research layers have not been published yet.

Featured By